Abstract 72P
Background
Ado-trastuzumab emtansine (T-DM1) became the first FDA approved antibody-drug conjugate in breast cancer. This real-world study aimed to evaluate the efficacy and safety of first approved T-DM1 biosimilar (ZRC-3256) in India for HER2-positive breast cancer in routine practice.
Methods
It was a retrospective, single-center, observational study and included patients treated between May 2021 to December 2022. Eligible patients were all female with HER2-positive metastatic breast cancer treated with trastuzumab and taxane prior and at progression treated with standard dose T-DM1 biosimilar. Brain metastasis patients treated with appropriate local therapy were allowed. The primary endpoint includes response rate and progression-free survival (PFS). The secondary endpoints were time to treatment failure (TTF), safety and overall survival (OS). Descriptive statistics were used to recapitulate the patient and other related characteristics. The study was approved by the institute ethics committee.
Results
30 patients treated with T-DM1 biosimilar were included. 5 among them had brain involvement. Median age was 57 years, all had received prior HER2-targeted therapy (100%) and majority of patients (86.67%) were post-menopausal. 83.3% patients received T-DM1 therapy in 2nd line and the complete response rate was 66.63%. Median progression free survival and time to treatment failure were found to be around 13.5 months (95% CI: 13.46 – 17.17) and 13 months (95% CI: 11.47 – 14.53) respectively. Median overall survival data is yet to mature and stand at 24 months (95% CI: 21.03 – 26.97) with limited events. Common adverse events were elevated transaminases, anemia, and thrombocytopenia, with most being manageable and reversible. 10% patients experienced adverse events of Grade 3 or above.
Conclusions
The study findings suggested that T-DM1 is effective in managing HER2-positive metastatic breast cancer and the outcomes with T-DM1 biosimilar usage in the real world are consistent with the published evidence of randomized controlled clinical trials with T-DM1. So, this biosimilar can be a reasonable option in routine clinical practice in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract